Replies to post #225005 on Biotech Values

[DewDiligence]

PFE—Bavencio trial in locally-advanced H&N cancer stopped for futility:

https://finance.yahoo.com/news/merck-pfizer-phase-iii-javelin-120000702.html

The JAVELIN study tested Bavencio as an adjunct to chemo and radiation in first-line, locally advanced SCCHN; the (failed) primary endpoint was PFS.

Note: PFE’s partner on this program is Merck KGaA (not MRK).